GLP1R and heart failure: These studies comparing SGLT2i and GLP1-RA individually with other oral therapies (predominantly DPP4i) generally reported average relative benefits for CVD and heart failure outcomes in-line with placebo-controlled trials, with no consistent pattern of subgroup level differences across studies (Supplementary Table 1a and 1b).